# The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

> **NCT06167681** · PHASE1,PHASE2 · RECRUITING · sponsor: **iRegene Therapeutics Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **BIOLOGICAL:** Human Dopaminergic Progenitor Cells

## Key facts

- **NCT ID:** NCT06167681
- **Lead sponsor:** iRegene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-17
- **Primary completion:** 2025-12
- **Final completion:** 2029-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06167681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06167681, "The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06167681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*